Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5753618	NOVARTIS	Somatostatin analogue composition and use in treating breast cancer	May, 2015 (8 years ago)
US5753618 (Pediatric)	NOVARTIS	Somatostatin analogue composition and use in treating breast cancer	Nov, 2015 (8 years ago)

Sandostatin is owned by Novartis.

Sandostatin contains Octreotide Acetate.

Sandostatin has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Sandostatin are:

Sandostatin was authorised for market use on 21 October, 1988.

Sandostatin is available in injectable;injection dosage forms.

The generics of Sandostatin are possible to be released after 19 November, 2015.

Market Authorisation Date: 21 October, 1988

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.05 mg /mL, 0.1 mg /mL and 0.5 mg/mL, 1 mL vials
0.2 mg/mL and 1 mg /mL, 5 mL vials
0.05 mg/mL (base), 0.1 mg/mL (base) and 0.5 mg/mL (base) packaged in 1 mL pre-filled syringes (preservative-free)	17 Jan, 2008	1	10 Feb, 2011	19 May, 2015	Extinguished Eligible

Strength	Dosage	Availability
EQ 1MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued
EQ 0.05MG BASE/ML	INJECTABLE;INJECTION	Prescription
EQ 0.1MG BASE/ML	INJECTABLE;INJECTION	Prescription
EQ 0.5MG BASE/ML	INJECTABLE;INJECTION	Prescription
EQ 0.2MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE;INJECTION	Discontinued

Sandostatin patents expiration